B-intervention	0	11	Anastrozole
O	12	18	versus
B-control	19	28	tamoxifen
O	29	31	as
O	32	37	first
O	37	38	-
O	38	42	line
O	43	50	therapy
O	51	53	in
B-eligibility	54	68	postmenopausal
I-eligibility	69	77	patients
I-eligibility	78	82	with
I-eligibility	83	90	hormone
I-eligibility	90	91	-
I-eligibility	91	100	dependent
I-eligibility	101	109	advanced
I-eligibility	110	116	breast
I-eligibility	117	123	cancer
O	123	124	:
O	125	126	a
O	127	138	prospective
O	138	139	,
O	140	150	randomized
O	150	151	,
O	152	157	phase
O	158	161	III
O	162	167	study
O	167	168	.

O	169	170	A
O	171	182	prospective
O	183	188	phase
O	189	192	III
O	193	198	trial
O	199	208	comparing
O	209	220	anastrozole
O	221	225	with
O	226	235	tamoxifen
O	236	238	as
O	239	244	first
O	244	245	-
O	245	249	line
O	250	257	therapy
O	258	260	in
O	261	275	postmenopausal
O	275	276	,
O	277	284	hormone
O	284	285	-
O	285	294	dependent
O	294	295	,
O	296	304	advanced
O	305	311	breast
O	312	318	cancer
O	319	320	(
O	320	323	ABC
O	323	324	)
O	324	325	.

O	326	334	Patients
O	335	339	were
O	340	350	randomized
O	351	353	to
O	354	365	anastrozole
O	366	367	1
O	368	370	mg
O	371	376	daily
O	377	378	(
O	378	379	n
O	380	381	=
B-intervention-participants	382	385	121
O	385	386	)
O	387	389	or
O	390	399	tamoxifen
O	400	402	40
O	403	405	mg
O	406	411	daily
O	412	413	(
O	413	414	n
O	415	416	=
B-control-participants	417	420	117
O	420	421	)
O	421	422	.

O	423	431	Efficacy
O	432	435	and
O	436	448	tolerability
O	449	453	were
O	454	463	evaluated
O	464	469	after
O	470	471	3
O	472	478	months
O	478	479	'
O	480	487	therapy
O	487	488	,
O	489	492	and
O	493	501	survival
O	502	505	was
O	506	515	evaluated
O	516	518	at
O	519	525	median
O	526	530	time
O	531	533	of
O	534	540	follow
O	540	541	-
O	541	543	up
O	543	544	.

O	545	547	At
O	548	549	a
O	550	556	median
O	557	563	follow
O	563	564	-
O	564	566	up
O	567	569	of
O	570	572	13
O	572	573	.
O	573	574	3
O	575	581	months
O	581	582	,
B-outcome	583	591	clinical
I-outcome	592	599	benefit
I-outcome	600	601	(
I-outcome	601	603	CB
I-outcome	603	604	)
O	605	608	was
O	609	617	achieved
O	618	620	in
B-iv-bin-percent	621	623	83
I-iv-bin-percent	623	624	%
O	625	628	and
B-cv-bin-percent	629	631	56
I-cv-bin-percent	631	632	%
O	633	635	of
O	636	647	anastrozole
O	648	651	and
O	652	661	tamoxifen
O	662	670	patients
O	670	671	,
O	672	684	respectively
O	685	686	(
O	686	687	p
O	688	689	<
O	690	691	0
O	691	692	.
O	692	695	001
O	695	696	)
O	696	697	;
B-outcome	698	704	median
I-outcome	705	709	time
I-outcome	710	712	to
I-outcome	713	720	disease
I-outcome	721	732	progression
I-outcome	733	734	(
I-outcome	734	737	TTP
I-outcome	737	738	)
O	739	741	in
O	742	750	patients
O	751	760	achieving
O	761	763	CB
O	764	767	was
B-iv-cont-median	768	770	18
I-iv-cont-median	770	771	.
I-iv-cont-median	771	772	0
I-iv-cont-median	773	779	months
O	780	783	and
B-cv-cont-median	784	785	7
I-cv-cont-median	785	786	.
I-cv-cont-median	786	787	0
I-cv-cont-median	788	794	months
O	794	795	,
O	796	808	respectively
O	808	809	,
O	810	811	(
O	811	817	hazard
O	818	823	ratio
O	824	825	[
O	825	827	HR
O	827	828	]
O	829	830	=
O	831	832	0
O	832	833	.
O	833	835	13
O	835	836	,
O	837	839	95
O	839	840	%
O	841	843	CI
O	844	845	=
O	846	847	0
O	847	848	.
O	848	850	08
O	850	851	-
O	851	852	0
O	852	853	.
O	853	855	20
O	855	856	,
O	857	858	p
O	859	860	<
O	861	862	0
O	862	863	.
O	863	865	01
O	865	866	)
O	866	867	.

O	868	870	At
O	871	875	data
O	876	882	cutoff
O	882	883	,
B-cv-bin-percent	884	886	89
I-cv-bin-percent	886	887	%
O	888	890	of
O	891	900	tamoxifen
O	901	909	patients
O	910	913	had
B-outcome	914	918	died
O	918	919	,
O	920	928	compared
O	929	933	with
B-iv-bin-percent	934	936	60
I-iv-bin-percent	936	937	%
O	938	940	of
O	941	952	anastrozole
O	953	961	patients
O	961	962	;
B-outcome	963	969	median
I-outcome	970	974	time
I-outcome	975	977	to
I-outcome	978	983	death
O	984	987	was
B-cv-cont-median	988	990	17
I-cv-cont-median	990	991	.
I-cv-cont-median	991	992	4
I-cv-cont-median	993	999	months
O	1000	1003	and
B-iv-cont-median	1004	1006	16
I-iv-cont-median	1006	1007	.
I-iv-cont-median	1007	1008	0
I-iv-cont-median	1009	1015	months
O	1015	1016	,
O	1017	1029	respectively
O	1030	1031	(
O	1031	1033	HR
O	1034	1035	=
O	1036	1037	0
O	1037	1038	.
O	1038	1040	64
O	1040	1041	,
O	1042	1044	95
O	1044	1045	%
O	1046	1048	CI
O	1049	1050	=
O	1051	1052	0
O	1052	1053	.
O	1053	1055	47
O	1055	1056	-
O	1056	1057	0
O	1057	1058	.
O	1058	1060	86
O	1060	1061	,
O	1062	1063	p
O	1064	1065	=
O	1066	1067	0
O	1067	1068	.
O	1068	1071	003
O	1071	1072	)
O	1072	1073	.

O	1074	1081	Therapy
O	1082	1085	was
B-outcome	1086	1090	well
I-outcome	1091	1100	tolerated
O	1101	1103	in
O	1104	1108	both
O	1109	1115	groups
O	1115	1116	.

O	1117	1128	Anastrozole
O	1129	1135	showed
O	1136	1147	significant
O	1148	1158	advantages
O	1159	1163	over
O	1164	1173	tamoxifen
O	1174	1177	for
B-outcome	1178	1180	CB
O	1180	1181	,
B-outcome	1182	1188	median
I-outcome	1189	1192	TTP
O	1193	1195	in
O	1196	1204	patients
O	1205	1212	gaining
O	1213	1215	CB
O	1215	1216	,
O	1217	1220	and
B-outcome	1221	1229	survival
O	1229	1230	.

O	1231	1236	These
O	1237	1241	data
O	1242	1249	further
O	1250	1257	support
O	1258	1265	routine
O	1266	1269	use
O	1270	1272	of
O	1273	1284	anastrozole
O	1285	1287	as
O	1288	1293	first
O	1293	1294	-
O	1294	1298	line
O	1299	1308	treatment
O	1309	1312	for
O	1313	1327	postmenopausal
O	1328	1335	hormone
O	1335	1336	-
O	1336	1345	dependent
O	1346	1349	ABC
O	1349	1350	.
